Figure 6: Improved clinical status of GRMD dogs injected with rAAV2/8-Spc5.12-cMD1 by the IV route.
From: Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
(a) The global clinical score was determined weekly and expressed as a percentage of a healthy dog score (100%) in untreated GRMD dogs (n=9, red lines) and GRMD dogs injected intravenously with rAAV2/8-Spc5.12-cMD1 at 2 × 1013 vg kg−1 (n=3, light grey dotted lines) or 1 × 1014 vg kg−1 (n=5, dark grey lines). For each dog, the line represents a tendency curve (mobile means order 3) built to show the score evolution. (b) The global clinical scores obtained in each dog at 6 months (left panel) and 9 months (right panel) of age were individually plotted for untreated GRMD dogs (n=9, red symbols), GRMD dogs injected intravenously with rAAV2/8-Spc5.12-cMD1 at 2 × 1013 vg kg−1 (n=3, grey symbols) or 1 × 1014 vg kg−1 (n=5, black symbols). Dead animals were reported with a clinical score at 0%. The horizontal bars represent the mean of the values obtained for each group. **P<0.01 (nonparametric Kruskal–Wallis test with post hoc multiple comparison Dunn’s test).
